At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
ACH-0144471drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Evaluate Efficacy and Safety of Long-Term Treatment With ACH-0144471 in Participants Who Completed Clinical Study ACH471-100
In Brief
A Phase 2 clinical trial evaluating ACH-0144471 for Paroxysmal Nocturnal Hemoglobinuria. Completed, enrolled 8 participants across 4 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the long-term safety and efficacy of ACH-0144471 in participants with paroxysmal nocturnal hemoglobinuria (PNH) who have demonstrated clinical benefit from ACH-0144471 in Study ACH471-100. This study is designed to include up to 12 participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Nocturnal Hemoglobinuria
CountriesItaly, New Zealand, South Korea
CollaboratorsAchillion, a wholly owned subsidiary of Alexion
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartJun 2017
Primary CompletionJan 2022
TodayJul 2026
First PostedJun 9, 2017
Enrollment StartJun 22, 2017
Primary CompletionJan 4, 2022
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 9.1 years ago
Interventions
ACH-0144471drug
ACH-0144471 will be administered to all participants enrolled in the study.